| アブストラクト | BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are promising weight-loss drugs, but real-world data concerning the liability of GLP-1RAs in gastrointestinal safety are lacking. We examined the differences in gastrointestinal safety between semaglutide and liraglutide. MATERIALS AND METHODS: We used the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database and retrieved data during the first three years of semaglutide and liraglutide approved by the FDA. Thirteen main gastrointestinal adverse drug reactions (GADRs) were evaluated. Patient demographics, treatment information, and outcome of events were summarized. Disproportionality analyses were conducted by estimating the reporting odds ratios (RORs) and 95% confidence intervals (CIs). RESULTS: In the reported cases of semaglutide (n = 2047) and liraglutide (n = 4175), semaglutide had a higher pooled ROR and later pooled time-to-onset median of GADRs compared with those of liraglutide (5.53, 95% CI 5.23-5.85 vs 3.95, 95% CI 3.81-4.10; 7 days, Q1-Q3: 0-48 vs 4 days, Q1-Q3: 0-34.5). The thirteen GADRs associated with these two GLP-1RAs showed a significant difference in the profile of reporting risk and time-to-onset. CONCLUSION: GLP-1RAs produce a spectrum of distinct classes of GADRs. The individual properties of GADRs between semaglutide and liraglutide might enable incretin-based treatment of obesity to be "tailored" to the needs of each patient. |
|---|
| ジャーナル名 | Diabetes, metabolic syndrome and obesity : targets and therapy |
|---|
| Pubmed追加日 | 2022/1/21 |
|---|
| 投稿者 | Zhou, Yu; Chen, Mingyu; Liu, Libin; Chen, Zhou |
|---|
| 組織名 | Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy,;Fujian Medical University, Fuzhou, People's Republic of China.;Department of Endocrinology, Fujian Medical University Union Hospital, Fuzhou,;People's Republic of China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35046686/ |
|---|
